Clinical Trial Update: Reirradiation With Concurrent Paclitaxel for Breast Cancer [Phase 1]

View source ↗

Summary

This Phase 1 trial assessing reirradiation with concurrent paclitaxel for breast cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: University of Kentucky | Conditions: Breast Cancer | Phase 1 | Status: WITHDRAWN